Skip to main content
. 2020 Jul 3;57:102858. doi: 10.1016/j.ebiom.2020.102858

Fig. 5.

Fig. 5

Evaluation of the PAMG in advanced disease. a. Univariate survival analysis using the OS of 47 patients in the BACAP cohort associated with either the PAMG or the PurIST two-subtype classification. b. Multivariate survival analysis forest plot for the BACAP cohort. c. Waterfall plot illustrating the change in tumour size induced by mFOLFIRINOX treatment evaluated by RECIST 1.1 in the COMPASS cohort (n = 28). Annotated Pearson's correlation between RECIST 1.1 and PAMG is shown.